
    
      The investigators omit basiliximab induction therapy in patients who underwent one to
      three-HLA mismatched living donor renal transplantation. Participants should receive ABO
      compatible and T-flow negative transplants. The investigators compare the results of
      intervention group with conventionally treated control group (age and sex matched patient who
      underwent one to three-HLA mismatched living donor renal transplants with basiliximab
      induction therapy).
    
  